Literature DB >> 24713361

The FXR agonist 6ECDCA reduces hepatic steatosis and oxidative stress induced by ethanol and low-protein diet in mice.

F A R Lívero1, Aline Maria Stolf1, Arturo Alejandro Dreifuss1, Amanda Leite Bastos-Pereira1, Raphaella Chicorski1, Liana Gomes de Oliveira1, Carlos Eduardo Alves de Souza1, Isabella Aviles Fabossi1, I S Rabitto1, Luiza Helena Gremski2, Raílson Henneberg3, José Ederaldo Queiroz Telles4, Ronald P J Oude Elferink5, Alexandra Acco6.   

Abstract

BACKGROUND AND AIM: Excessive ethanol consumption can lead to development of hepatic steatosis. Since the FXR receptor regulates adipose cell function and liver lipid metabolism, the aim of this work was to examine the effects of the FXR agonist 6ECDCA on alcoholic liver steatosis development and on oxidative stress induced by ethanol consumption.
METHODS: Swiss mice (n=24) received a low-protein diet (6%) and a liquid diet containing 10% ethanol or water for 6weeks. In the last 15days mice received oral treatment with 6ECDCA (3mgkg(-1)) or 1% tween (vehicle). The experimental groups (n=6) were: water+tween, water+6ECDCA, ethanol+tween and ethanol+6ECDCA. Moreover, as a diet control, we used a basal group (n=6), fed by a normal-proteic diet (23%) and water. After the treatment period, the animals were anesthetized for sample collection to perform plasma biochemistry assays, hepatic oxidative stress assays, hepatic cholesterol and triglycerides measurements, liver histology and hepatic gene expression.
RESULTS: Ethanol associated with low-protein diet induced hepatic oxidative stress, increased plasma transaminases and induced hepatic lipid accumulation. Many of these parameters were reversed by the administration of 6ECDCA, including amelioration of lipid accumulation and lipoperoxidation, and reduction of reactive oxygen species. These effects were possibly mediated by regulation of Srebpf1 and FAS gene expression, both reduced by the FXR agonist.
CONCLUSIONS: Our data demonstrated that 6ECDCA reverses the accumulation of lipids in the liver and decreases the oxidative stress induced by ethanol and low-protein diet. This FXR agonist is promising as a potential therapy for alcoholic liver steatosis.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  6ECDCA; Ethanol; FXR; Liver; Oxidative stress; Steatosis

Mesh:

Substances:

Year:  2014        PMID: 24713361     DOI: 10.1016/j.cbi.2014.03.014

Source DB:  PubMed          Journal:  Chem Biol Interact        ISSN: 0009-2797            Impact factor:   5.192


  20 in total

1.  FXR deletion in hepatocytes does not affect the severity of alcoholic liver disease in mice.

Authors:  Min Zhang; Bo Kong; Mingxing Huang; Ruixuan Wan; Laura E Armstrong; Justin D Schumacher; Daniel Rizzolo; Monica D Chow; Yi-Horng Lee; Grace L Guo
Journal:  Dig Liver Dis       Date:  2018-04-23       Impact factor: 4.088

2.  Current Management and Future Treatment of Alcoholic Hepatitis.

Authors:  Mack C Mitchell; Thomas Kerr; H Franklin Herlong
Journal:  Gastroenterol Hepatol (N Y)       Date:  2020-04

Review 3.  FXR Agonists: From Bench to Bedside, a Guide for Clinicians.

Authors:  Ahmad Samer Alawad; Cynthia Levy
Journal:  Dig Dis Sci       Date:  2016-10-12       Impact factor: 3.199

Review 4.  Insulin resistance in clinical and experimental alcoholic liver disease.

Authors:  Rotonya M Carr; Jason Correnti
Journal:  Ann N Y Acad Sci       Date:  2015-05-21       Impact factor: 5.691

Review 5.  FXR agonists as therapeutic agents for non-alcoholic fatty liver disease.

Authors:  Rotonya M Carr; Andrea E Reid
Journal:  Curr Atheroscler Rep       Date:  2015-04       Impact factor: 5.113

Review 6.  Farnesoid X receptor: a master regulator of hepatic triglyceride and glucose homeostasis.

Authors:  Yang Jiao; Yan Lu; Xiao-ying Li
Journal:  Acta Pharmacol Sin       Date:  2014-12-15       Impact factor: 6.150

Review 7.  New insights into the bile acid-based regulatory mechanisms and therapeutic perspectives in alcohol-related liver disease.

Authors:  Yali Liu; Tao Liu; Xu Zhao; Yanhang Gao
Journal:  Cell Mol Life Sci       Date:  2022-08-17       Impact factor: 9.207

8.  Biliary cirrhosis-induced cardiac abnormality in rats: Interaction between Farnesoid-X-activated receptors and the cardiac uncoupling proteins 2 and 3.

Authors:  Gholamreza Bayat; Seyed Ali Hashemi; Hosein Karim; Parviz Fallah; Keshvad Hedayatyanfard; Mahnaz Bayat; Azadeh Khalili
Journal:  Iran J Basic Med Sci       Date:  2022-01       Impact factor: 2.532

9.  Croton urucurana Baill. Ameliorates Metabolic Associated Fatty Liver Disease in Rats.

Authors:  Pablo Alvarez Auth; Gustavo Ratti da Silva; Eduarda Carolina Amaral; Victor Fajardo Bortoli; Mariana Inocencio Manzano; Lauro Mera de Souza; Evellyn Claudia Wietzikoski Lovato; João Tadeu Ribeiro-Paes; Arquimedes Gasparotto Junior; Francislaine Aparecida Dos Reis Lívero
Journal:  Front Pharmacol       Date:  2022-05-20       Impact factor: 5.988

10.  Hydroethanolic extract of Baccharis trimera promotes gastroprotection and healing of acute and chronic gastric ulcers induced by ethanol and acetic acid.

Authors:  Francislaine Aparecida Dos Reis Lívero; Luisa Mota da Silva; Daniele Maria Ferreira; Larissa Favaretto Galuppo; Debora Gasparin Borato; Thiago Bruno Lima Prando; Emerson Luiz Botelho Lourenço; Regiane Lauriano Batista Strapasson; Maria Élida Alves Stefanello; Maria Fernanda de Paula Werner; Alexandra Acco
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-06-17       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.